Related Experiment Video
Updated: May 29, 2026

Modified Single-Loop Reconstruction for Pancreaticoduodenectomy
Published on: September 28, 2019
Resolution of a posttraumatic pancreatic pseudocyst with octreotide acetate in a pediatric patient
Insights
Higher doses of octreotide acetate combined with surgical interventions offer a faster resolution for pediatric pancreatic pseudocysts. This approach led to rapid pseudocyst resolution in an 11-day treatment period.
Area of Science:
- Pediatric Surgery
- Gastroenterology
- Trauma Management
Background:
- Pancreatic pseudocysts are a known complication of abdominal trauma in children.
- Octreotide acetate is an established adjunct therapy for pancreatic pseudocysts.
- Literature on octreotide acetate for pediatric pancreatic pseudocysts is limited.
Abstract:
A pancreatic pseudocyst is a complication of abdominal trauma in pediatric patients. Octreotide acetate is an effective adjunct therapy used in combination with traditional surgical approaches. We describe a 19-month-old boy with a pancreatic pseudocyst secondary to blunt abdominal trauma who was successfully managed with octreotide acetate in combination with percutaneous drainage and the placement of a pancreatic stent. Octreotide acetate 1 μg/kg/hour was administered as a continuous intravenous infusion for 24 hours, followed by 2.5 μg/kg/dose every 12 hours subcutaneously for 11 days. The patient was discharged after the pseudocyst had resolved and oral feeding was restored. He had no recurrence of the pseudocyst. The published literature regarding octreotide acetate therapy for pediatric pancreatic pseudocysts is limited. Previously reported cases demonstrated successful resolution of pancreatic pseudocysts with varying doses of intravenous and subcutaneous octreotide acetate within 23-30 days; however, with our patient's regimen, along with surgical interventions, the pseudocyst resolved within 11 days. In addition, our patient's regimen involved higher doses of octreotide acetate given more frequently than those reported in the literature. This case report illustrates that use of higher octreotide acetate dosages may be a potential adjunct therapy to surgical interventions for the management of pancreatic pseudocysts in children.
